Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27787837
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27787837
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Hypertens+Rep
2016 ; 18
(11
): 83
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Effects of Aspirin on Endothelial Function and Hypertension
#MMPMID27787837
Dzeshka MS
; Shantsila A
; Lip GY
Curr Hypertens Rep
2016[Nov]; 18
(11
): 83
PMID27787837
show ga
PURPOSE OF REVIEW: Endothelial dysfunction is intimately related to the
development of various cardiovascular diseases, including hypertension, and is
often used as a target for pharmacological treatment. The scope of this review is
to assess effects of aspirin on endothelial function and their clinical
implication in arterial hypertension. RECENT FINDINGS: Emerging data indicate the
role of platelets in the development of vascular inflammation due to the release
of proinflammatory mediators, for example, triggered largely by thromboxane.
Vascular inflammation further promotes oxidative stress, diminished synthesis of
vasodilators, proaggregatory and procoagulant state. These changes translate into
vasoconstriction, impaired circulation and thrombotic complications. Aspirin
inhibits thromboxane synthesis, abolishes platelets activation and acetylates
enzymes switching them to the synthesis of anti-inflammatory substances. Aspirin
pleiotropic effects have not been fully elucidated yet. In secondary prevention
studies, the decrease in cardiovascular events with aspirin outweighs bleeding
risks, but this is not the case in primary prevention settings. Ongoing trials
will provide more evidence on whether to expand the use of aspirin or stay within
current recommendations.